Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database

BACKGROUND AND OBJECTIVE: Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of prespecified outcomes in patients with RA, PsA or AS...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziyadeh, Najat J., Geldhof, Anja, Noël, Wim, Otero-Lobato, Marijo, Esslinger, Suzan, Chakravarty, Soumya D., Wang, Yiting, Seeger, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595963/
https://www.ncbi.nlm.nih.gov/pubmed/32779120
http://dx.doi.org/10.1007/s40261-020-00959-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595963/
https://www.ncbi.nlm.nih.gov/pubmed/32779120
http://dx.doi.org/10.1007/s40261-020-00959-7

Ejemplares similares